The current valuation score of Enlivex Therapeutics Ltd is 9.88, ranking 8 out of 389 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.02, which is 93.04% below the recent high of 0.04 and 13807.83% above the recent low of -3.15.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.